Help us to stop prostate diseases ruining lives
UPDATE - Issue 05 - March 2000
Needle-less injection progress
PowderJect, the company we reported on in the last issue of Update, has reported encouraging results from its phase two trial of the erectile dysfunction drug alprostadil with actual sufferers. There is now clear proof of the clinical concept. The company has also strengthened its commercial opportunity in this growing market by securing the rights to a low cost, high quality source of the drug alprostadil.